Wednesday, 05 Nov 2025

ctDNA Test is Predictive of Adjuvant Atezolizumab Benefit in MIBC

Written by
Cancer Network
Published
Patients with muscle-invasive bladder cancer with a positive Signatera test displayed a significant improvement in disease-free and overall survival.
Tags:
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago